Food and Drug Administration

Pediatric Advisory Committee

April 11, 2007

Slides

One Year Post-Exclusivity Adverse Event Review: Lescol ® , Lescol XL ® (fluvastatin sodium), Amy M. Taylor, MD, MHS, FAAP, FDA (ppt) (htm)

One Year Post Exclusivity Adverse Event Review Update: Orlistat, Hari Cheryl Sachs, MD, FAAP, FDA (ppt) (htm)

Update to the Committee: Oxybutynin Central Anticholinergic Effects, Andrew D. Mosholder, M.D., M.P.H. , FDA (ppt) (htm)

One Year Post-Exclusivity Adverse Event Review: Sandostatin ® injection and LAR (octreotide) , Amy M. Taylor, MD, MHS, FAAP, FDA (ppt) (htm)

---

Up | AC Home Page